Cost-effectiveness analysis and innovation

Journal of Health Economics

Volumn 27, Issue 5, 2008, Pages 1224-1236

  Jena, Anupam B ^a   Philipson, Tomas J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cost effectiveness; Dynamic efficiency; R D; Surplus appropriation

Indexed keywords

COST-BENEFIT ANALYSIS; HEALTH CARE; INNOVATION; TECHNOLOGICAL CHANGE;

ARTICLE; BEHAVIOR; COST EFFECTIVENESS ANALYSIS; HEALTH CARE; HEALTH CARE COST; MEDICAL TECHNOLOGY; PATENT; RESOURCE ALLOCATION; STATISTICAL ANALYSIS;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DIFFUSION OF INNOVATION; EFFICIENCY, ORGANIZATIONAL; HEALTH CARE SECTOR; HEALTH SERVICES NEEDS AND DEMAND; HEALTH SERVICES RESEARCH; HUMANS; INVESTMENTS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 50249188242     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2008.05.010     Document Type: Article

References (31)

1. Arrow K. Economic welfare and the allocation of research for invention. In: Nelson E.R. (Ed). The Rate and Direction of Inventive Activity: Economic and Social Factors (1961), Princeton University Press
2. Bethan G., Harris A., and Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991-1996). Pharmacoeconomics 11 (2001) 1103-1109
3. Caves, R., Whinston, M., Hurwitz, M., 1991. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Brookings Paper on Microeconomic Activity, Microeconomics, pp. 1-66.
4. Cutler D.M. Your Money or Your Life: Strong Medicine for America's Health Care System (2004), Oxford University Press, New York, NY
5. Cutler D.M., and McClellan M. Is technological change in medicine worth it?. Health Affairs 20 (2001) 11-29
6. Drummond M., et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health 2 (1999) 323-332
7. Drummond M., et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 4 (1993) 173-186
8. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes (1997), Oxford University Press
9. Garber, A.M., 1999. Advances in Cost-Effectiveness Analysis of Health Interventions. NBER Working Paper 7198.
10. Garber A.M., and Phelps C.E. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16 (1997) 1-32
11. Garber, A.M., Jones, C.I., Romer, P.M., 2006. Insurance and incentives for medical innovation. BE Press Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy, Article 4.
12. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press
13. Hall B.H. In: Smith B., and Barfield C. (Eds). The Private and Social Returns to Research and Development, Technology, R&D and the Economy (1996), Brookings Institution/American Enterprise Institute
14. Johannesson M., and Weinstein M.C. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 12 (1993) 459-467
15. Lakdawalla, D., Sood, N., 2005. Insurance and Innovation in Health Care Markets. NBER Working Paper.
16. Levin R.C., Klevorick A.K., Nelson R.R., Winter S.G., Gilbert R., and Griliches Z. Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity 3 (1987) 783-831
17. Manning R.L. Changing rules in the Tort Law and the market for childhood vaccines. Journal of Law and Economics 37 (1994) 247-275
18. Mansfield E. How rapidly does new technology leak out?. The Journal of Industrial Economics 34 (1985) 217-223
19. Mansfield E., Rapoport J., Romeo A., Wagner S., and Beardsley G. Social and private rates of return from industrial innovation. The Quarterly Journal of Economics 91 (1977) 221-240
20. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics 16 (1997) 33-64
21. Neumann P.J., Sandberg E.A., Bell C.M., Stone P.W., and Chapman R.H. Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs 19 (2000) 92-109
22. Newhouse J. Medical care costs: how much welfare loss?. Journal of Economic Perspectives 6 3 (1992) 3-21
23. Nordhaus, W.D., 2004. Schumpeterian Profits in the American Economy: Theory and Measurement. NBER Working Paper.
24. Phelps C.E., and Parente S.T. Priority setting in medical technology and medical practice assessment. Medical Care 28 (1990) 03-723
25. Philipson T. In: Newhouse J., and Culyer A. (Eds). Economic Epidemiology and Infectious Disease, Chapter in Handbook of Health Economics (2000), Elsevier B.V., North Holland
26. Philipson, T., Jena, A.B., 2005. Who Benefits from Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs. Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy, Article 3. Berkeley Electronic Press (Also NBER Working Paper #11810).
27. Philipson, T., Jena, A.B., Mechoulan, S., 2006. Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets. NBER Working Paper #11930.
28. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on new health technologies. British Medical Journal 323 (2001) 1300-1303
29. Tirole J. The Theory of Industrial Organization (1988), The MIT Press
30. Weinstein M.C., and Manning Jr. W.G. Theoretical issues in cost-effectiveness analysis. Journal of Health Economics 16 (1997) 121-128
31. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296 (1977) 716-721